NCI Cancer and Inflammation Program researchers developed multiple novel human anti-HIV-1 domain antibodies and their fusion proteins with two-domain or single-domain human soluble CD4 that can potentially be used alone or synergistically with other anti-HIV-1 antibodies and antiretroviral drugs as therapeutics and/or preventatives for infection by different HIV-1 strains. These are available for co-development and licensing.
Inhibition of delta133p53 may be a novel approach for cell senescence-mediated anti-proliferative therapy, including anti-cancer treatments. In addition, enhanced expression of delta 133p53 can extend the replicative lifespan of normal human cells. Therefore, this technology may provide a new method in the field of regenerative medicine for aging-related degenerative disease as well as cancer therapeutics. The National Cancer Institute seeks parties to co-develop or license a new method for inhibiting aging-related degenerative disease and cancer.
The Nanotechnology Characterization Laboratory of the Frederick National Laboratory for Biomedical Research seeks parties interested in collaborative research to co-develop a ceramide and vinca alkaloid combination therapy for treatment of cancer.
The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.
Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen. Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill human tumor cells endogenously expressing the native MUC-1 epitope.
The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.
The NCI Radiation Oncology Branch and the NHLBI Laboratory of Single Molecule Biophysics seek parties to co-develop fluorescent nanodiamonds for use as in vivo and in vitro optical tracking probes toward commercialization.
The National Cancer Institute, Laboratory of Molecular Biology is seeking parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers.
The National Cancer Institute’s Surgery Branch seeks partners interested in collaborative research to co-develop adoptive transfer of tumor infiltrating leukocytes (TIL) for cancers other than melanoma.
The National Cancer Institute, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Retroviral and Lentiviral Vectors
The National Cancer Institute’s Nanobiology Program seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications.
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.
The National Cancer Institute Laboratory of Molecular Pharmacology seeks parties interested in licensing or collaborative research to co-evelop, evaluate, or commercialize lasonolide compounds as novel anti-cancer agents.
Nitric oxide (NO) plays an important role as a major intrinsic vasodilator, and increases blood flow to tissues and organs. Disruption of this process leads to peripheral vascular disease, ischemic heart disease, stroke, vascular insufficiency associated with diabetes, and many more diseases that are significant. Researchers at the NIH have discovered that the matrix protein thrombospondin-1 blocks the beneficial effects of NO, and prevents it from dilating blood vessels and increasing blood flow to organs and tissues. The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in licensing or collaborative research to co-develop therapeutics targeting vasodialation.